Biogen Inc BIIB:NASDAQ (Common Stock)

LastChange / % ChangeDividend YieldVolumeAvg Volume (10 day)
290.04 3.18   1.11%1,684,2821.6M
Market data is delayed by at least 15 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Market is closed. Chart as of 04:00 PM ET 12/1/2015

Latest News Headlines for Biogen Inc

Sobi and Biogen's ELOCTA(R) (rFVIIIFc) Approved in Europe for the Treatment of Haemophilia A

First therapy to provide prolonged bleeding protection with prophylactic injections every three to five days Product to launch in initial EU countries in early 2016 STOCKHOLM & CAMBRIDGE, Mass.--(BUSINESS WIRE)--November 24, 2015--

View more recent headlines

Peers Information HelpBIIB Biogen Inc vs. Peers

Biogen Inc
Johnson & Johnson
Pfizer Inc.
Merck & Co., Inc.
AbbVie Inc
Biogen Inc
Johnson & Johnson
Pfizer Inc.
Merck & Co., Inc.
AbbVie Inc
Biogen Inc
Johnson & Johnson
Pfizer Inc.
Merck & Co., Inc.
AbbVie Inc
Compare these stocks

Latest Annual and Quarterly SEC Filings

More Filings

This report contains detailed information about the company's business finances and management.


Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Biogen Inc., formerly Biogen Idec Inc., is a global biopharmaceutical company. The Company is focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. The Company develops, manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Company's marketed products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, FAMPYRA for multiple sclerosis (MS), ALPROLIX for hemophilia B, and ELOCTATE for hemophilia A, among others. It also collaborates on the development and commercialization of RITUXAN (rituximab), which is a monoclonal antibody for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA, which is for the treatment of chronic lymphocytic leukemia.


collapse, right-facing arrow indicating collapsed view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open289.30
Previous Close286.86
Day High290.59
Day Low285.80
52 Week High3/20/2015 | 480.18
52 Week Low10/15/2015 | 254.00
% Off 52 Week High-39.60%
% Off 52 Week Low14.19%
Beta (5 Yr)0.87
Volatility Avg12/1/2015 | 42.39
10-Day Avg. Volume1,599,518
Market data is delayed by at least 15 minutes.

collapse, right-facing arrow indicating collapsed view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)9/30/2015 | 15.31
P/E Ratio9/30/2015 | 19.1
Market CapLarge Cap | 64.7B
Shares Outstanding222.90M

collapse, right-facing arrow indicating collapsed view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield--
Dividend Announcement--
Date of Record--
Payable-- - --
Payable Date--

collapse, right-facing arrow indicating collapsed view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short3.04M
Short Ratio1.4
Short % of Float1.36%
As of 11/15/2015